123 related articles for article (PubMed ID: 34998121)
41. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
42. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
[TBL] [Abstract][Full Text] [Related]
43. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
44. Development of autotaxin inhibitors: A series of zinc binding triazoles.
Thomson CG; Le Grand D; Dowling M; Brocklehurst CE; Chinn C; Elphick L; Faller M; Freeman M; Furminger V; Gasser C; Hamadi A; Hardaker E; Head V; Hill JC; Janus DI; Pearce D; Poulaud AS; Stanley E; Sviridenko L
Bioorg Med Chem Lett; 2018 Jul; 28(13):2279-2284. PubMed ID: 29798825
[TBL] [Abstract][Full Text] [Related]
45. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
46. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
47. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
[TBL] [Abstract][Full Text] [Related]
48. Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
Kaffe E; Katsifa A; Xylourgidis N; Ninou I; Zannikou M; Harokopos V; Foka P; Dimitriadis A; Evangelou K; Moulas AN; Georgopoulou U; Gorgoulis VG; Dalekos GN; Aidinis V
Hepatology; 2017 Apr; 65(4):1369-1383. PubMed ID: 27981605
[TBL] [Abstract][Full Text] [Related]
49. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
50. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
51. The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage.
Sakai N; Bain G; Furuichi K; Iwata Y; Nakamura M; Hara A; Kitajima S; Sagara A; Miyake T; Toyama T; Sato K; Nakagawa S; Shimizu M; Kaneko S; Wada T
Sci Rep; 2019 May; 9(1):7414. PubMed ID: 31092842
[TBL] [Abstract][Full Text] [Related]
52. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity.
Kang TS; Wang W; Zhong HJ; Liang JX; Ko CN; Lu JJ; Chen XP; Ma DL; Leung CH
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):256-263. PubMed ID: 27888146
[TBL] [Abstract][Full Text] [Related]
53. Positron Emission Tomography Imaging of Autotaxin in Thyroid and Breast Cancer Models Using [
Litchfield M; Wuest M; Glubrecht D; Briard E; Auberson YP; McMullen TPW; Brindley DN; Wuest F
Mol Pharm; 2021 Sep; 18(9):3352-3364. PubMed ID: 34319110
[TBL] [Abstract][Full Text] [Related]
54. Autotaxin: structure-function and signaling.
Perrakis A; Moolenaar WH
J Lipid Res; 2014 Jun; 55(6):1010-8. PubMed ID: 24548887
[TBL] [Abstract][Full Text] [Related]
55. Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.
Madan D; Ferguson CG; Lee WY; Prestwich GD; Testa CA
PLoS One; 2013; 8(11):e79065. PubMed ID: 24278115
[TBL] [Abstract][Full Text] [Related]
56. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase/phosphodiesterase inhibitors and antiproliferative agents.
Ullah S; El-Gamal MI; El-Gamal R; Pelletier J; Sévigny J; Shehata MK; Anbar HS; Iqbal J
Eur J Med Chem; 2021 May; 217():113339. PubMed ID: 33744686
[TBL] [Abstract][Full Text] [Related]
58. Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis.
Cao P; Walker NM; Braeuer RR; Mazzoni-Putman S; Aoki Y; Misumi K; Wheeler DS; Vittal R; Lama VN
Sci Rep; 2020 Dec; 10(1):21231. PubMed ID: 33277571
[TBL] [Abstract][Full Text] [Related]
59. Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice.
Dong YL; Duan XY; Liu YJ; Fan H; Xu M; Chen QY; Nan Z; Wu H; Deng SJ
Inflammation; 2019 Oct; 42(5):1530-1541. PubMed ID: 31102124
[TBL] [Abstract][Full Text] [Related]
60. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature.
Castagna D; Budd DC; Macdonald SJ; Jamieson C; Watson AJ
J Med Chem; 2016 Jun; 59(12):5604-21. PubMed ID: 26745766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
